eFFECTOR Therapeutics IPO

effector.com

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Founded2012
Total Funding to Date$152.08MM
Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

eFFECTOR Therapeutics Ticker Symbol

eFFECTOR Therapeutics does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

eFFECTOR Therapeutics Stock Price

The stock price for eFFECTOR Therapeutics will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

eFFECTOR Therapeutics Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
8/24/2017 Series C $197.73MM $XXX.XX $XXX.XX
12/22/2015 Series B $141.22MM $XXX.XX $XXX.XX
5/20/2013 Series A $67.04MM $XXX.XX $XXX.XX
Based on primary financings

Other companies like eFFECTOR Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B